InterAx: InterAx Biotech's platform enables AI-based modification of drug candidates

Villigen-based InterAx Biotech has completed its two-year Horizon 2020-project "PICARD" successfully and four months in advance to the deadline. The grant enabled InterAx to expand its platform. Thanks to the integration of AI it is now able to actively determine how to modify the chemistry of drug candidates to improve efficacy and safety.